Krystal Biotech, Inc. reported a net income of $204.8 million for the year ended December 31, 2025, a significant increase compared to the $89.2 million net income in 2024 and the $10.9 million net income in 2023. This financial turnaround is primarily attributed to the commercial success of VYJUVEK, which generated $389.1 million in net product revenue in 2025, compared to $290.5 million in 2024 and $50.7 million in 2023. The company's gross margin remained strong at 94% for 2025, consistent with the previous two years.
Operating expenses totaled $227.8 million in 2025, a slight increase from $224.8 million in 2024 and a more substantial rise from $160.3 million in 2023. Research and development expenses increased to $58.0 million in 2025, up from $53.6 million in 2024 and $46.4 million in 2023, reflecting ongoing investments in the company's pipeline. Selling, general, and administrative expenses also rose to $146.7 million in 2025, compared to $113.6 million in 2024 and $98.3 million in 2023, driven by increased commercialization efforts for VYJUVEK and expansion of the company's infrastructure. A litigation settlement expense of $37.5 million was recorded in 2024, compared to $12.5 million in 2023 and none in 2025.
Key operational developments included the continued commercial rollout of VYJUVEK in the United States, Germany, France, and Japan. The company is also actively engaged in pricing negotiations in key European markets and advancing discussions for potential launches in other regions. In January 2026, Krystal Biotech announced positive interim clinical data from the Phase 1 CORAL-1 study of KB407 for cystic fibrosis, confirming successful lung delivery and expression of wild-type CFTR protein. The company is working with the Cystic Fibrosis Foundation Therapeutic Development Network on a repeat dosing study design, CORAL-3, expected to begin enrollment in the first half of 2026.
Looking ahead, Krystal Biotech expects to continue investing in its research and development pipeline, expanding its commercial infrastructure, and pursuing regulatory approvals for its product candidates in key markets. The company's financial position remains strong, with cash, cash equivalents, and short-term investments totaling $827.8 million as of December 31, 2025. Management believes these resources will be sufficient to fund operations for at least the next 12 months. The company's future success depends on the continued commercial performance of VYJUVEK, the successful development and regulatory approval of its product candidates, and its ability to manage its growing operations effectively.
About Krystal Biotech, Inc.
Krystal Biotech is a biotechnology company specializing in gene therapies for rare and serious diseases. Using its proprietary HSV-1 platform, it develops and commercializes treatments like VYJUVEK for dystrophic epidermolysis bullosa and pipeline candidates for ophthalmology, respiratory, oncology, and dermatology. The company focuses on non-invasive, repeatable gene delivery to address high unmet medical needs globally.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.